Evaluating TACE with immunotherapy for liver cancer treatment
Retrospective Study and Construction of a Prediction Model for Patients With Intermediate and Advanced Liver Cancer Treated With TACE Combined With Immunotherapy and Targeted Therapy
Qianfoshan Hospital · NCT06205732
This study is testing whether combining a liver cancer treatment called TACE with immunotherapy and targeted therapy can help people with intermediate and advanced liver cancer do better than TACE alone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qianfoshan Hospital (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06205732 on ClinicalTrials.gov |
What this trial studies
This study assesses the effectiveness and safety of transarterial chemoembolization (TACE) combined with immunotherapy and targeted therapy compared to TACE alone in patients with intermediate and advanced liver cancer. It aims to identify factors influencing prognosis and develop an individualized prognostic score and risk stratification model for these patients. The study is observational and will analyze existing patient data to draw conclusions about treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed primary liver cancer and specific liver function and performance status criteria.
Not a fit: Patients with liver metastatic cancer, severe comorbidities, or those who have undergone certain previous treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes and survival rates for patients with intermediate and advanced liver cancer.
How similar studies have performed: Other studies have shown promising results with similar combinations of TACE and immunotherapy, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years old, both men and women * primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings * patients with liver function Child-Pugh A or B (≤8 points) * BCLC stage B and stage C * expected survival time ≥8 weeks * patients with generally good performance status (ECOG PS score 0 or 1) Exclusion Criteria: * The patient's key data is missing * liver metastatic cancer confirmed by histology or cytology * patients who interrupt treatment due to intolerance of adverse drug reactions * combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc. * combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation * study participants known to have mental illness * situations such as drug use or substance abuse
Where this trial is running
Jinan, Shandong
- the Qianfoshan Hospital — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Jing Liang, Dr
- Email: liangjing0531@163.com
- Phone: 0086-18663761275
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Carcinoma, Hepatocellular